Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
None listed
Sponsors
AstraZeneca Pharma India Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who are ready to provide written informed consent 2. Patients of both genders of > 18 years of age 3. Newly diagnosed breast cancer patients who may or may not have undergone primary surgery with or without radiotherapy, and who have not yet completed their first line of systemic therapy. First line therapy is defined as neo(adjuvant) chemotherapy/ hormonal therapy/HER2 targeted therapy.
Exclusion criteria
Exclusion criteria: 1. Patients with breast cancer with HER2 IHC 2+, in whom in situ hybridization (ISH) is not done or not planned to be done. 2. Patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of newly diagnosed breast cancer patients with pathogenic or likely pathogenic BRCA1 or BRCA 2 mutationsTimepoint: Single visit | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the percentage of pathogenic/likely pathogenic germline BRCA1 mutation in comparison to pathogenic/likely pathogenic germlineBRCA2 mutation in Indian population.Timepoint: Single visit | — |
Countries
India
Contacts
Public ContactAmit Kumar
AstraZeneca Pharma India Ltd
Outcome results
None listed